Everand Logo

Welcome to Everand!

  • Discover millions of ebooks, audiobooks, and so much more with a free trial

    From $11.99/month after trial. Cancel anytime.

    Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A practical resource for nurses
    Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A practical resource for nurses
    Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A practical resource for nurses
    Ebook127 pages1 hour

    Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A practical resource for nurses

    By R.J. Buka and D. Moloney

    ()

    Read preview

    About this ebook

    Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine. Table of Contents: • DLBCL: an overview • CAR T cells • CAR T-cell products • Delivering CAR T-cell therapy and managing patient expectations • CAR T-cell therapy-related toxicities
    LanguageEnglish
    PublisherS. Karger
    Release dateSep 30, 2021
    ISBN9783318069358
    Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma: A practical resource for nurses

    Related to Fast Facts

    Related ebooks

    Medical For You

    View More
    View More

    Related podcast episodes

    Related articles

    • UNLIMITED

      Opinion: 5 Tips for Creating Effective Biotech Partnerships

      Jan 8, 2018

      I've been on both sides of forging biotech partnerships. Here are five tips for creating good ones.

      4 min read

    • UNLIMITED

      What Defines a Stem Cell?

      Dec 27, 2018

      For the past three years, researchers at the Hubrecht Institute in the Netherlands have been painstakingly cataloging and mapping all the proliferating cells found in mouse hearts, looking for cardiac stem cells. The elusive cells should theoreticall

      5 min read

    • UNLIMITED

      Beating Cancer

      Feb 1, 2019

      Is cancer still a death sentence? No. Most cancers are preventable and also treatable. Cancer diagnosis and treatment have grown by leaps and bounds. We know the cause of at least 70 per cent of cancers now, around 60 per cent of cancers are now prev

      4 min read

    • UNLIMITED

      Coping with... LUNG CANCER

      Dec 29, 2022

      Coping with... LUNG CANCER
      2 min read

    • UNLIMITED

      Healing The Whole Person

      Jul 24, 2022

      The UK National Health Service reports that one in two people in the UK will develop cancer at some time in their lives. This is a stark and rather frightening statistic, not only because cancer is a leading cause of death but also because the usual

      7 min read

    • UNLIMITED

      Coping with... LUNG CANCER

      Jan 13, 2021

      Primary lung cancer is the third commonest cancer in the UK. Around 47,000 UK people are diagnosed yearly, with 45% aged 75 or over, and slightly more men than women. More than 70 out of 100 UK lung cancer cases are caused by smoking. Other risks inc

      1 min read

    • UNLIMITED

      The Best Integrative Cancer Specialists

      Nov 21, 2021

      The Best Integrative Cancer Specialists
      5 min read

    • UNLIMITED

      Groundbreaking Research

      Apr 19, 2019

      Groundbreaking Research
      2 min read

    • UNLIMITED

      Detecting Cancer At The Earliest Stages

      Jul 24, 2022

      Detecting Cancer At The Earliest Stages
      7 min read

    • UNLIMITED

      THE renaissance OF CELL THERAPIES

      Jul 28, 2019

      DR MARKUS DEPFENHART, PLASTIC AND AESTHETIC SURGEN In the late 1990s and early 2000s, there was huge hype around stem cells and their apparently almost unlimited potential, but unfortunately the expectations didn’t materialise. However, new scientifi

      2 min read

    • UNLIMITED

      Coping with RECTAL CANCER

      Jun 8, 2022

      Coping with RECTAL CANCER
      2 min read

    • UNLIMITED

      WINNING The War Against CANCER

      Jan 21, 2021

      WINNING The War Against CANCER
      3 min read

    • UNLIMITED

      TOP Five MEDICAL Breakthroughs

      Feb 20, 2018

      TOP Five MEDICAL Breakthroughs
      2 min read

    • UNLIMITED

      Thrombotic Thrombocytopenic Purpura (TTP) – a Rare Presentation with COVID-19

      Sep 1, 2022

      1 Department of General Medicine, Aster MIMS Hospital, Kozhikode, Kerala, India 2 Department of Nephrology, Aster MIMS Hospital, Kozhikode, Kerala, India Dr. Jabir M P, Consultant, Department of General Medicine, Aster MIMS, Kozhikode-673016 Email: j

      5 min read

    • UNLIMITED

      Coping with CHRONIC LYMPHOCYTIC LEUKAEMIA

      Apr 14, 2021

      In CLL, the bone marrow produces too many lymphocyte-type white blood cells, which aren’t functioning properly, causing an increased infection risk and persistent tiredness. CLL is different from other types of leukaemia. The cause isn’t clear, there

      1 min read

    • UNLIMITED

      Life Force

      Sep 1, 2022

      Life Force
      6 min read

    Related categories

    Reviews for Fast Facts

    0 ratings

    0 ratings0 reviews

    What did you think?

    Tap to rate

    Review must be at least 10 words

      Book preview

      Fast Facts - R.J. Buka

      Introduction

      Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine.

      Here, as well as providing an overview of how CAR T cells work, current and emerging products and the results of clinical trials, we look at the key role of nurses in the education of, and communication with, patients and caregivers and the multidisciplinary delivery and coordination of CAR T-cell therapy. Clear and accurate patient education and good communication and coordination between the treatment center and the referring center, leading up to and following CAR T-cell therapy, is essential for successful outcomes in eligible patients.

      In particular, we look at the nurse’s role in managing the frequent short-term toxicities associated with CAR T-cell therapy and longer-term monitoring, as well as how to manage patients’ treatment expectations. We hope this will be a valuable resource for all nurses caring for patients and the needs of their family members, as well as other members of the multidisciplinary team.

      Hematopoiesis is the highly controlled process by which blood cells are made and mature. It can go wrong at any point, by virtue of numerous genetic faults, resulting in distinctly different diseases. Lymphomas are cancers that originate from lymphoid cells – T lymphocytes (T cells), B lymphocytes (B cells), natural killer cells – and their progenitors (Figure 1.1). As the name suggests, diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells.

      Epidemiology and classification

      Simplistically, lymphomas can be categorized as Hodgkin lymphoma and non-Hodgkin lymphoma (NHL), with the latter further subcategorized as high-grade (aggressive disease) or low-grade (slow-growing, indolent disease) NHL. Through the course of the disease, low-grade lymphoma can transform into high-grade lymphoma. This is important for CAR T-cell approvals, which are discussed later. NHL makes up around 4% of all cancer cases in both the UK and USA.¹,² DLBCL not otherwise specified (NOS) is the most common high-grade lymphoma, comprising 30–40% of all NHL.³,⁴ It is an aggressive cancer with a median age of onset of about 70 years and has a slight male predominance.

      Figure 1.1 Development of lymphoid cells from hematopoietic stem cells (HSC) to terminally differentiated cells through intermediate progenitors.

      Subclassification. Gene expression profiling (GEP) can be used to subclassify DLBCL NOS into two principal molecular subtypes.⁵

      •The germinal center B-cell-like (GCB) subtype is derived from B cells in the germinal center of secondary lymphoid organs.

      •The activated B-cell-like (ABC) subtype is derived from a more mature stage in the B-cell life cycle after it has traversed the germinal center.

      Defining these two DLBCL subtypes has prognostic relevance, as GCB-DLBCL has a significantly better prognosis than ABC-DLBCL.⁶,⁷ As GEP is not in mainstream clinical use, analysis of immunohistochemical staining patterns can be used to assign the subtype.⁸

      Finally, there are a number of lymphomas that are closely related to DLBCL, including primary mediastinal B-cell lymphoma, primary CNS lymphoma and testicular lymphoma. The distinctions are beyond the scope of this book but are important, as they may require specific treatments and may or may not be eligible for CAR T-cell therapy.

      Diagnosis

      Clinical presentation. DLBCL may present with enlarged lymph nodes and/or symptoms that include fever, weight loss or night sweats, otherwise known as ‘B symptoms’.⁹

      Many conditions can mimic lymphoma, including infectious diseases such as Epstein–Barr virus (EBV), tuberculosis and syphilis, autoimmune diseases such as sarcoidosis, and benign self-limiting conditions such as Kikuchi lymphadenitis.

      Although DLBCL is often confined to the lymph nodes (‘nodal’ disease), as lymphocytes reside in other tissues it can also involve extranodal sites, including the gastrointestinal tract, lungs, skin, kidneys, adrenal glands, brain, bones and other soft tissues, and can thus present in many different ways.

      Work-up should include a detailed history and examination, extensive blood work-up and cross-sectional imaging. Formal diagnosis requires histological assessment of affected tissue. A surgical excisional lymph-node biopsy is the gold standard investigation because it usually provides ample tissue to allow thorough histological assessment of the nodal architecture.¹⁰,¹¹ However, a core-needle biopsy is frequently performed as it is straightforward to arrange and can often yield a diagnosis.

      Figure 1.2 Hematoxylin–eosin-stained section of DLBCL showing sheets of large pleomorphic malignant lymphoid cells.

      Immunohistopathological examination is the key to diagnosis; DLBCL is characterized by diffuse infiltration and effacement of the normal architecture of affected lymph nodes by sheets of large lymphomatous B cells (Figure 1.2), which stain positive for B-cell markers, including CD19, CD20, CD79a and surface immunoglobulin (Ig) M.

      Staging

      DLBCL is staged from the results of imaging and biopsy.

      •Stage I: involvement of one lymph node region (a node or group of adjacent nodes) or localized involvement of a single extralymphatic site (stage IE).

      •Stage II: involvement of two or more lymph nodes on the same side of the diaphragm or localized involvement of a single extralymphatic site and one or more lymph nodes on the same side of the diaphragm (stage IIE).

      •Stage III: involvement of lymph nodes on both sides of the diaphragm.

      •Stage IV: widespread disease with involvement of one or more extralymphatic organs with or without lymph-node involvement.

      Estimating prognosis

      The revised International Prognostic Index (R-IPI) is a widely used five-parameter prognostic scoring system that predicts outcomes in patients with DLBCL treated with R-CHOP immunochemotherapy (discussed below).¹² A more recent iteration of the score, the National Comprehensive Cancer Network IPI (NCCN-IPI), uses the same parameters but with more categories and different weighting, thereby better distinguishing clinically important risk groups (Table 1.1).¹³

      Knowing the cell of origin and the molecular features of the disease can further refine prognosis when used in conjunction with the NCCN-IPI score.¹⁴ As discussed above, GCB-DLBCL has a more favorable prognosis than the ABC subtype. Rearrangements or amplifications of the genes MYC, BCL2 or BCL6 may lead to their increased expression, conferring a survival advantage on the tumor cells. In around 10% of cases of DLBCL, the MYC gene is rearranged in combination with either or both of the BCL2 or BCL6 genes, forming double- or triple-hit lymphomas, which have a poorer prognosis.¹⁵ Chromosomal translocations involving MYC, BCL2 and/or BCL6 lead to high overexpression in lymphoma cells, endowing them with a

      Enjoying the preview?
      Page 1 of 1